Running multiple compounds affecting gut function simultaneously can amplify these effects beyond tolerable levels
To prevent ROS production from semiquinones, the cytosolic, NRF2-regulated flavoproteins NAD(P)H: quinone oxidoreductases (NQOs) and aldo-keto reductase (AKR) can compete with P450 reductases and convert quinones to a relatively stable hydroquinones (quinols) [35]
Acts upstream of, and synergizes with, GHS-R1a (ghrelin-receptor) agonists such as Ipamorelin in paired secretagogue studies
18-h: j , k ) (n = 3, two-sided unpaired t-test)
62 GLP-1 receptor activation inhibits glucagon secretion, whereas GIP receptor activation increases glucagon secretion during normoglycemia or hypoglycemia, but suppresses glucagon secretion under hyperglycemic conditions
Think of hypothalamic hormones at the top of the chain -- like the the CEO -- and "all sh*t rolls downhill"